We conducted a prospective observational study to assess the incidence of residual neuromuscular blockade (RNMB) in a post-anaesthetic care unit (PACU) of a tertiary hospital. The subjects were 102 patients undergoing general anaesthesia with neuromuscular blockade (NMB). The procedural anaesthetists were unaware of their patients' inclusion in the study, and the choice of muscle relaxant and use of reversal agents were at the anaesthetists' discretion. On arrival to the PACU, the train-of-four ratio was assessed using electromyography, repeated every five minutes until the train-of-four ratio exceeded 0.9. RNMB was defined as a train-of-four ratio <0.9. The requirement for airway support, incidence of desaturation while in the PACU and time to eligibility for PACU discharge were recorded. The mean interval between the last dose of relaxant and arrival in the PACU for patients with RNMB was 81 minutes. An intermediate-acting muscle relaxant had been used for most patients. Despite this, RNMB was observed in 31% (95% confidence interval 25 to 47%) of patients. Our findings suggest that RNMB in the PACU is common. As RNMB may predispose to postoperative complications, anaesthetists should utilise quantitative monitoring to assess neuromuscular blockade and optimise reversal use. Anaesthetists should be aware that intervals between the last dose of relaxant of well over one hour do not exclude the possibility of RNMB, even when using intermediate-acting neuromuscular blockade agents.
Neuromuscular blocking drugs are utilised during general anaesthesia to facilitate instrumentation of the airway and mechanical ventilation and to improve operating conditions. Non-depolarising agents are competitive antagonists of nicotinic acetylcholine receptors at the neuromuscular junction whose effect degrades with time after administration. To facilitate resumption of efficient spontaneous ventilation during and after emergence from anaesthesia, neuromuscular blockade (NMB) should have dissipated or have been reversed using an anticholinesterase such as neostigmine. The status of blockade is most commonly monitored by evaluating fade in twitches during four sequential electrical stimuli ('train-offour') applied to a nerve while contraction in the target muscle is subjectively or objectively monitored. Residual neuromuscular blockade (RNMB) is defined as a train-of-four ratio (TOFR) <0.9 1 . In the last two decades RNMB has been identified as a frequent clinical problem with potential negative consequences for patients. While a TOFR >0.7 was traditionally considered as adequate recovery from NMB 2 , volunteer trials have indicated that a TOFR <0.9 is associated with the possibility of aspiration 3 , an impaired ventilatory response to hypoxia 4 and increased upper airway collapsibility 5 . Residual NMB has also been associated with postoperative pulmonary complications 6 and with critical respiratory events in the post-anaesthetic care unit (PACU) 7 .
Although the introduction of intermediateacting muscle relaxants, such as vecuronium and atracurium, has helped to reduce its incidence, RNMB continues to occur 8 . A large scale audit of patients in the PACU of a French hospital showed that 16% have a TOFR <0.7 and 45% have a TOFR <0.9 9 . We aimed to investigate the incidence of RNMB in our hospital. Secondary aims were to audit the incidence of the need for airway support, the incidence of desaturation and the time to eligibility for discharge from the PACU in patients with and without RNMB.
MATERiAlS AND METHODS
Auckland City Hospital is a 570-bed tertiary teaching hospital situated in a major metropolitan area that serves 420,700 people. The department in which the research was carried out employs 32 specialist anaesthetists and 18 trainees. Following ethics committee approval in April 2006, we prospectively recruited 102 patients with American Society of Anesthesiologists (ASA) physical status I to III who were scheduled to undergo elective or emergency surgery for general, vascular, neurosurgical, urological, hepatobiliary and orthopaedic procedures, over a six-month period from April to September 2006. This was a sample of convenience and recruitment depended on the availability of a researcher on any particular day. Inclusion criteria were the planned use of NMB and the ability of the patient to provide informed consent. Exclusion criteria were patient refusal, allergy to gel electrodes and known neuromuscular disease. The study was designed to be generalised to the population of adult patients undergoing surgery in our hospital, so patients were not excluded on the basis of hepatic or renal comorbidities.
Anaesthetists were blinded to patient involvement in the study and recruited patients were asked not to discuss their participation with their attending anaesthetist. The conduct of anaesthesia, including the choice of muscle relaxant and the use of neuromuscular monitoring, was at the discretion of the anaesthetist. In accordance with Australian and New Zealand College of Anaesthetists (ANZCA) standards, peripheral nerve stimulators suitable for monitoring the train-of-four were present in every operating room. To ensure the anaesthetists remained blinded to their participation in the study, we did not attempt to observe the use or interpretation of TOFRs intraoperatively. All patients were extubated in the operating room prior to transfer to the PACU.
The primary outcome variable was RNMB (defined as TOFR <0.9) at any time during the patient's PACU stay. On arrival in the PACU, two cutaneous electrodes were placed over the ulnar nerve and a 30 mA submaximal stimulus was applied as a trainof-four. The motor response at adductor pollicis was measured using a Datex electromyographic monitor (Datex instrumentation Corp., Helsinki, Finland) to quantify the TOFR. The use of submaximal stimuli to ensure patient comfort has been previously validated as accurate in measuring TOFRs in this context 10 . Measurements were repeated until two consecutive TOFRs were within 10% of each other and these were later averaged for analysis. Where patient movement obviously confounded the measurement, the value was discarded and the stimulus repeated. in patients where the 30 mA stimulus was insufficient to elicit a train-of-four response, the stimulus was increased gradually (in 5 mA increments) until consistent measurements were obtained. Train-of-four stimulations were repeated every five minutes until the TOFR was >0.9. When patients had a TOFR persistently below 0.7 for more than 10 minutes, their attending anaesthetist was contacted and asked to consider administering neostigmine. The PACU nurses monitored and maintained core body temperature above 35°C in all patients as part of standard care.
On the basis of these measurements, patients were stratified into two groups defined by the presence or absence of RNMB (TOFR <0.9). The groups were compared with respect to secondary outcomes applicable to the PACU stay, which included: the need for airway support (defined as jaw thrust, insertion of nasopharyngeal, oropharyngeal or laryngeal mask airway or reintubation); the incidence of desaturation (which we defined by an oxygen saturation of less than 90% while receiving oxygen via Hudson mask); the time from arrival in PACU to eligibility for discharge (defined by an Aldrete score 11 >9); and the time to actual discharge. The groups were also compared with respect to patient and perioperative variables thought to be possible associations with RNMB, including: weight; gender; ASA score; procedural acuity (elective/emergent); duration of surgery; reversal (neostigmine) administration; elapsed time between last dose of neuromuscular blocking agent and arrival in PACU; and the cumulative dose of neuromuscular blocking agent administered (normalised to the duration of the operation).
The groups were compared using unpaired t-tests with respect to continuous variables and chi-square or Fisher's exact tests with respect to categorical variables. Differences were considered statistically significant when P was <0.05.
RESUlTS
All patients who gave consent and received NMB agents (n=102) were assessed upon their arrival in PACU. However, movement repeatedly interfered with measurement of TOFR in eight cases, so 94 patients were included in our analysis. The mean (SD) patient age was 57 (16) years, weight was 80 (21) kg with equal numbers of males and females. Sixteen patients were scored as ASA I, 44 as ASA II and 34 as ASA III.
Eighty-two patients (87%) had elective surgery and 12 (13%) underwent emergency surgery. General surgery accounted for 71% of cases, urology 11% and vascular surgery, orthopaedics and neurosurgery 6% each. Eighty-two (87%) patients were given atracurium, eight (9%) vecuronium and four (4%) rocuronium. Six patients received succinylcholine as part of a rapid sequence induction, followed by a non-depolarising blocking agent, most commonly atracurium. Neostigmine was given as reversal agent to 61 (65%) patients.
On arrival in the PACU, 29 patients (31%: 95% confidence interval 25 to 47%) were found to have RNMB with an average TOFR of 0.62 (range 0.24 to 0.89). This resolved in all patients within 55 minutes (Figure 1) .
A greater proportion of patients with RNMB required airway support than those with TOFR >0.9 (Table 1) . Patients with RNMB were more likely to be male, have had a shorter duration of anaesthesia, larger doses of muscle relaxant and to have had a shorter time interval between the last dose of relaxant administration and arrival in PACU ( Table 2) .
The incidence of RNMB was not significantly lower in patients who had received neostigmine. Three patients whose TOFRs were sustained below 0.7 for more than 10 minutes were given a dose of neostigmine in the PACU by their attending anaesthetist. For two of these patients the TOFR rose to >0.7 within 10 minutes, but one patient had a TOFR <0.7 for a further 20 minutes. Too few patients received either vecuronium or rocuronium to permit comparing the incidence of RNMB between different relaxant groups. Analysis of the 82 patients who received atracurium showed that patients with RNMB had received a significantly higher cumulative dose ( Table 2) .
DiSCUSSiON
Thirty-one percent of patients exhibited RNMB (TOFR <0.9) on arrival in our PACU. Ours is the first published audit of RNMB from Australasia. While our results may not necessarily apply to other centres, they suggest a lower incidence of RNMB in our PACU than the 41.3% reported in a previous multicentre meta-analysis of 3375 patients 12 . The possible associations with RNMB identified in our audit are also consistent with previous studies, which have shown that RNMB is associated with a higher cumulative dose of neuromuscular blocking drug 13 , a shorter interval between final dose and arrival in the PACU 13, 14 and a shorter duration of anaesthesia 14 .
Interestingly, RNMB occurred in our patients despite an average of 81 minutes between the last dose of relaxant given and patient arrival in the PACU ( Table 2) . Although the manufacturer's data for atracurium describe a 95% recovery from an ED 95 dose in 60 to 70 minutes 15 , additional factors may extend this recovery period. Prolonged blockade can occur through interactions with other drugs, physiological variables such as temperature and comorbidities such as renal or hepatic disease 16 . The duration of action of rocuronium has also been shown to be influenced by time of day 17 . These factors, combined with multiple dosing, make expected recovery times harder to predict. It is notable that patients without RNMB in this study had a significantly longer interval between the last dose of muscle relaxant and arrival in the PACU ( Table 2) , but the study design limits any inference that can be drawn here.
Notwithstanding debate over the clinical significance of RNMB, there is reasonable evidence that it is potentially harmful 6, 7, 18 and this raises the question of how best to ensure adequate recovery from NMB while maintaining efficient theatre use throughout. The first step is to assess the level of NMB remaining at the end of the procedure. However, anaesthetists should bear in mind that even under optimal conditions in which an experienced operator detects no difference in the twitches induced by double-burst stimulation, clinically significant NMB may still be present 18, 19 . This is not to say that the technique has no value, but there needs to be an appreciation of the fact that it may produce false negatives. More objective quantitative techniques to measure TOFR are available and several authors have argued for their routine use over tactile assessment 18, [20] [21] [22] . The frequent occurrence of RNMB in this audit, together with previous findings of potential associated complications 6 , provides some support for this argument. For those patients displaying RNMB, reversal agents may be employed, which can effectively reverse partial non-depolarising NMB. However, this too can be problematic and previous work has failed to find an association between neostigmine use and a lower incidence of RNMB, once this has occurred 10 . This may reflect the importance of the timing of neostigmine administration. In particular, neostigmine has limited efficacy against profound blockade 8 . In this context, it is notable that current research on sugammadex (Org 25969) suggests that this reversal agent can be administered effectively even for relatively profound blockade of rocuronium 23, 24 .
Our study has a number of limitations that must be acknowledged. First, the sample is small and was completed at a single centre, making it difficult to generalise these results beyond our study site. Second, we did not monitor the status of NMB in the operating room, particularly at times when decisions about reversal were made. This limits our ability to comment on the value of neostigmine administration in preventing RNMB. Unfortunately, observations in the operating room could not be performed without unblinding anaesthetists. Third, our use of desaturation in PACU as an outcome measure is potentially confounded by the fact that we did not record variations in oxygen administration by the PACU nurses. Thus, a patient's tendency to desaturate may have been masked by more aggressive oxygen therapy. Nor did we collect sedation scores, which also complicates interpretation of the incidence of desaturation in the PACU and prevents us from drawing conclusions about the apparent association between RNMB and the increased need for airway support (Table 1) . Finally, the participating anaesthetists' preference for atracurium precluded comparison of different muscle relaxants. While our decision not to exclude patients on the basis of hepatic or renal comorbidities may be viewed as a limitation, we feel that these are well known patient states that should be considered during the use and management of NMB. Therefore we have included them in this audit of the incidence of RNMB.
Our study shows that RNMB occurs frequently in our unit despite the avoidance of long-acting muscle relaxants and compliance with ANZCA guidelines 25 regarding the availability of nerve stimulators in every operating room. ANZCA guidelines are similar to other professional guidelines internationally 26 . In the near future, newer agents may help to prevent RNMB from occurring. In the meantime, anaesthetists should consider quantitative monitoring to assess NMB and optimise reversal use and be aware that intervals between the last dose of relaxant and extubation/transfer to the PACU of well over an hour do not exclude the possibility of RNMB when using intermediate-acting NMB agents.
